Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TYK2 inhibitor

- PMLiVE

Astellas poaches new oncology head from Takeda

Claire Thom is named senior VP of global oncology development

- PMLiVE

Boehringer’s first cancer drug leads EMA recommendations

Afatinib recommended for lung cancer under brand name Giotrif

- PMLiVE

Non-amyloid therapies emerging for Alzheimer’s at AAIC

AAIC meeting hears new clinical data from Lundbeck, Baxter, Chiesi and Takeda

- PMLiVE

New formulations of Pralia and Enbrel head list of new drugs in Japan

Regulator backs medicines from Pfizer, Takeda, Daiichi Sankyo, Astellas, Zeria and otsuka

- PMLiVE

Death leads to recall of batch of Takeda’s Rienso in Switzerland

Marketing partner Amag also reports three other hypersensitivity reactions

- PMLiVE

New vortioxetine studies reinforce efficacy in depression

Supports marketing applications from Takeda and Lundbeck

- PMLiVE

Takeda rides out Actos decline as fiscal 2012 sales rise

Nycomed acquisition continues to bolster revenues

- PMLiVE

Takeda buys vaccines specialist Inviragen

Acquires vaccine candidates against dengue fever and hand, foot and mouth disease in $250m deal

- PMLiVE

US-based Millennium launches blood cancer website

The Takeda Oncology Company roll out new multiple myeloma website

- PMLiVE

Pharma companies partner with Japanese government

GHIT Fund will support development of medicines for infectious diseases in developing countries

- PMLiVE

Takeda files lymphoma drug brentuximab vedotin in Japan

Seeks approval for antibody-drug conjugate for two forms of the blood cancer

- PMLiVE

Takeda suspended as vice president of Japanese industry body

Mis-labelling also prompts JPMA to takes action against CMO Nihon Pharmaceutical

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links